Biotech News

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

Prime Medicine (PRME)Prime Medicine2026-07-08 12:00 ESTCompany update

-- Arbitration tribunal declared that PM647 is within Prime Medicine’s “Field”, confirming Prime Medicine’s right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to Beam Therapeutics -- -- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in

Prime Medicine

Prime Editing Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo. PM577 PM577 is an in vivo Prime Editing candidate designed to...

Recent company news

PRMEPrime Medicine2026-08-06 12:00 EST

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

PRMEPrime Medicine2026-07-23 20:05 EST

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

PRMEPrime Medicine2026-07-08 12:00 EST